bimekizumab (Pending FDA Approval)

Brand and Other Names:
  • Print

Dosing & Uses

Plaque Psoriasis

Pending FDA approval for moderate-to-severe plaque psoriasis

Next:

Pharmacology

Mechanism of Action

Humanized monoclonal IgG1 antibody that selectively inhibits interleukin-17A (IL-17A) and IL-17F

Interleukins are naturally occurring cytokines involved in normal inflammatory and immune responses and play a key role in the pathogenesis of plaque psoriasis

Previous
Next:

Images

Previous
Next:
Medscape prescription drug monographs are based on FDA-approved labeling information, unless otherwise noted, combined with additional data derived from primary medical literature.